Isofol Medical AB (publ) financials
Isofol Medical AB (publ)
549300MCXYAHG7VBHX75 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | SEK 12.8M | SEK 22.4M |
| Other income | SEK 59.0K | SEK 0 |
| Operating expenses | SEK 180.3M | SEK 226.9M |
| Employee benefits expense | SEK 34.7M | SEK 27.7M |
| Depreciation & amortisation | SEK 1.6M | SEK 1.6M |
| Operating profit (EBIT) | -SEK 167.5M | -SEK 204.5M |
| Net finance income / (cost) | SEK 7.7M | SEK 4.2M |
| Finance costs | SEK 44.0K | SEK 168.0K |
| Profit before tax | -SEK 159.8M | -SEK 200.3M |
| Income tax expense | SEK 0 | SEK 0 |
| Profit for the year | -SEK 159.8M | -SEK 200.3M |
| — attributable to owners | -SEK 159.8M | -SEK 200.3M |
| Total comprehensive income | -SEK 159.8M | -SEK 200.3M |
| Per share | ||
| Basic EPS | SEK -0.99 | SEK -1.59 |
| Diluted EPS | SEK -0.99 | SEK -1.59 |
| Free cash flow / share | SEK -1.18 | SEK -1.50 |
| Cash flow statement | ||
| Net cash from operating activities | -SEK 191.0M | -SEK 188.4M |
| Net cash from investing activities | SEK 0 | SEK 0 |
| Purchase of PP&E (capex) | SEK 0 | SEK 0 |
| Net cash from financing activities | -SEK 1.7M | SEK 450.5M |
| Lease liability payments | SEK 1.7M | SEK 1.5M |
| Net change in cash | -SEK 192.7M | SEK 262.0M |
| Balance sheet | ||
| Total assets | SEK 213.5M | SEK 401.4M |
| Non-current assets | SEK 4.0M | SEK 6.8M |
| Property, plant & equipment | SEK 4.0M | SEK 1.7M |
| Intangible assets & goodwill | SEK 0 | SEK 0 |
| Current assets | SEK 209.5M | SEK 394.6M |
| Trade & other receivables | SEK 0 | SEK 0 |
| Cash & equivalents | SEK 190.6M | SEK 379.4M |
| Total equity | SEK 158.5M | SEK 318.2M |
| Non-current liabilities | SEK 3.3M | SEK 110.0K |
| Lease liabilities (non-current) | SEK 2.4M | SEK 110.0K |
| Current liabilities | SEK 51.7M | SEK 83.0M |
| Trade & other payables | SEK 7.5M | SEK 17.7M |
| Derived metrics | ||
| Free cash flow | -SEK 191.0M | -SEK 188.4M |
| Operating margin | -1308.6% | -912.5% |
| Net margin | -1248.4% | -893.7% |
| Return on equity | -100.8% | -62.9% |
| Cash conversion ratio | 1.20× | 0.94× |
| Other reported items | ||
| Accruals and Deferred Income Including Contract Liabilities | SEK 40.9M | SEK 62.1M |
| Additional Paidin Capital | SEK 1.22B | SEK 1.22B |
| Adjustments For Decrease Increase In Other Operating Receivables | -SEK 504.0K | SEK 9.9M |
| Adjustments For Increase Decrease In Other Operating Payables | -SEK 31.2M | SEK 4.9M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -SEK 159.3M | -SEK 203.2M |
| Current Prepaid Expenses | SEK 1.2M | SEK 2.9M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | SEK 3.8M | SEK 1.0M |
| Equity and Liabilities | SEK 213.5M | SEK 401.4M |
| Finance Income | SEK 7.8M | SEK 4.4M |
| Income Taxes Paid Refund Classified As Operating Activities | SEK 0 | SEK 0 |
| Increase Decrease In Working Capital | SEK 31.7M | -SEK 14.8M |
| Increase Decrease Through Transactions With Owners | — | SEK 451.9M |
| Intangible Assets Other Than Goodwill | SEK 0 | SEK 0 |
| Issued Capital | SEK 4.9M | SEK 4.9M |
| Liabilities | SEK 55.0M | SEK 83.1M |
| Noncurrent Financial Assets | SEK 0 | SEK 5.0M |
| Other Adjustments For Noncash Items | SEK 450.0K | -SEK 2.9M |
| Other Comprehensive Income | SEK 0 | SEK 0 |
| Other Expense By Nature | SEK 142.1M | SEK 196.7M |
| Other Gains Losses | -SEK 1.8M | -SEK 843.0K |
| Other Liabilities | SEK 3.3M | SEK 3.2M |
| Other Noncurrent Financial Assets | SEK 0 | SEK 5.0M |
| Other Property Plant and Equipment | SEK 4.0M | SEK 1.7M |
| Other Provisions | SEK 845.0K | SEK 0 |
| Other Receivables | SEK 17.7M | SEK 12.3M |
| Proceeds From Issuing Other Equity Instruments | SEK 23.0K | SEK 108.0K |
| Proceeds From Issuing Shares | SEK 0 | SEK 451.9M |
| Retained Earnings | -SEK 904.3M | -SEK 704.1M |
| Revenue and Operating Income | SEK 12.9M | SEK 22.4M |
| Share Issue Related Cost | — | SEK 48.2M |
Every line item above is a fact tagged in Isofol Medical AB (publ)'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (SEK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.